0.665

0.05% 0.0003

Pre-market: .68 0.015 +2.26%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $0.665, with a volume of 1.00M. It is up +0.05% in the last 24 hours and up +35.52% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$0.6647

Open:

$0.68

24h Volume:

1.00M

Relative Volume:

0.76

Market Cap:

$151.86M

Revenue:

$8.95M

Net Income/Loss:

$-21.49M

P/E Ratio:

-5.5417

EPS:

-0.12

Net Cash Flow:

$-29.24M

1W Performance:

-4.82%

1M Performance:

+35.52%

6M Performance:

+12.98%

1Y Performance:

-33.50%

1-Day Range:

$0.6501

$0.6838

1-Week Range:

$0.64

$0.76

52-Week Range:

$0.3651

$1.15

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2025-03-10

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	0.665	155.94M	8.95M	-21.49M	-29.24M	-0.12
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

May 27, 2025

Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com

May 27, 2025

May 26, 2025

B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings - Defense World

May 26, 2025

May 21, 2025

Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com

May 21, 2025

May 19, 2025

Cell Therapy Manufacturing Market Is Booming Worldwide | WuXi - openPR.com

May 19, 2025

May 17, 2025

Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright - Defense World

May 17, 2025

May 16, 2025

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans - MSN

May 16, 2025

Comerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 16, 2025

May 15, 2025

Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 15, 2025

Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 15, 2025

May 14, 2025

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Inve - GuruFocus

May 14, 2025

Lineage Cell Therapeutics Q1 2025 Earnings: EPS Beats Estimates at -$0.02, Revenue Misses at $1.5 Million - GuruFocus

May 14, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire

May 14, 2025

Wells Fargo & Company MN Increases Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

May 14, 2025